专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130217913A1 Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient 有权
标题翻译：包括阿拉霉素或其衍生物的抗疟药物作为活性成分
公开(公告)号：US20130217913A1
公开(公告)日：2013-08-22
申请号：US13883038
申请日：2011-11-09
申请人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
发明人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
IPC分类号： A61K31/197 , A61K31/16 , A61K31/221
CPC分类号： A61K31/197 , A61K9/0019 , A61K9/107 , A61K9/2018 , A61K9/2027 , A61K31/16 , A61K31/221 , Y02A50/411
摘要： Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R3 represents hydrogen or a methyl group).
摘要翻译：本发明提供疟疾的预防和/或治疗剂，其包含作为活性成分的5-乙酰氨基-4-氧代-5-己烯酸（阿拉霉霉素）或其衍生物。使用疟疾的预防和/或治疗剂，其包含作为活性成分的由式（I）表示的阿拉霉素或其衍生物（其中R 1表示羟基，氨基或取代或未取代的直链或支链烷氧基或碳原子数为1〜8的烷基氨基; R2表示氢，取代或未取代的碳原子数1〜8的直链或支链烷基或取代或未取代的碳原子数4〜10的芳基，R3表示氢或甲基）。

2. 发明授权

US09295660B2 Antimalarial drug comprising alaremycin or derivative thereof as active ingredient 有权
标题翻译：抗疟药包含阿拉霉素或其衍生物作为活性成分
公开(公告)号：US09295660B2
公开(公告)日：2016-03-29
申请号：US13883038
申请日：2011-11-09
申请人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
发明人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
IPC分类号： A61K31/197 , A61K31/16 , A61K31/221 , A61K9/00 , A61K9/107 , A61K9/20
CPC分类号： A61K31/197 , A61K9/0019 , A61K9/107 , A61K9/2018 , A61K9/2027 , A61K31/16 , A61K31/221 , Y02A50/411
摘要： Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R3 represents hydrogen or a methyl group).
摘要翻译：本发明提供疟疾的预防和/或治疗剂，其包含作为活性成分的5-乙酰氨基-4-氧代-5-己烯酸（阿拉霉霉素）或其衍生物。使用疟疾的预防和/或治疗剂，其包含作为活性成分的由式（I）表示的阿拉霉素或其衍生物（其中R 1表示羟基，氨基或取代或未取代的直链或支链烷氧基或碳原子数为1〜8的烷基氨基; R2表示氢，取代或未取代的碳原子数1〜8的直链或支链烷基或取代或未取代的碳原子数4〜10的芳基，R3表示氢或甲基）。

3. 发明授权

US07033802B1 Penicillin binding protein gene and process for producing L-glutamic acid 失效
标题翻译：青霉素结合蛋白基因及产生L-谷氨酸的方法
公开(公告)号：US07033802B1
公开(公告)日：2006-04-25
申请号：US09623596
申请日：1999-03-05
申请人： Masaaki Wachi , Kazuo Nagai
发明人： Masaaki Wachi , Kazuo Nagai
IPC分类号： C12P13/14
CPC分类号： C12P13/14 , C07K14/34
摘要： The present invention relates to a penicillin binding protein, DNA encoding the protein and methods of producing L-glutamic acid in Corynebacterium glutamicum, which has a reduction of penicillin binding protein activity.
摘要翻译：本发明涉及青霉素结合蛋白，编码蛋白质的DNA以及谷氨酸棒杆菌中产生L-谷氨酸的方法，其具有青霉素结合蛋白活性的降低。

4. 发明授权

US07855228B2 Antibiotics targeting MreB 有权
标题翻译：针对MreB的抗生素
公开(公告)号：US07855228B2
公开(公告)日：2010-12-21
申请号：US11350966
申请日：2006-02-08
申请人： Zemer Gitai , Lucy Shapiro , Masaaki Wachi , Noritaka Iwai
发明人： Zemer Gitai , Lucy Shapiro , Masaaki Wachi , Noritaka Iwai
IPC分类号： C07C335/32 , A61K31/215
CPC分类号： C12Q1/18 , A61K31/17 , Y02A50/473 , Y02A90/22
摘要： The identification of MreB as essential for bacterial chromosome segregation provides a new target for antibiotic action. The MreB function is useful in the development of screening assays for new antibiotics, which may use, for example, genetic mutants in MreB, tests of MreB mediated chromosome segregation, and the like. In one embodiment of the invention, the antibiotic is an isothiourea compound, which may comprise a polyhalogenated benzyl group, e.g. at the 4 position, the 2,4 position, etc. A pharmaceutical composition comprising an MreB targeted antibiotic as an active agent is administered to a patient suffering from a microbial infection, particularly bacterial infections.
摘要翻译：鉴定MreB是细菌染色体分离所必需的，为抗生素作用提供了新的靶标。 MreB功能可用于开发新抗生素的筛选测定，其可以使用例如MreB中的遗传突变体，MreB介导的染色体分离的测试等。在本发明的一个实施方案中，抗生素是异硫脲化合物，其可以包含多卤代苄基，例如，在4位，2,4位等。将包含MreB靶向抗生素作为活性剂的药物组合物施用于患有微生物感染，特别是细菌感染的患者。

5. 发明申请

US20050054062A1 Gene conferring lysozyme insensitivity to Corynebacterium 有权
标题翻译：基因赋予溶菌酶对棒状杆菌不敏感
公开(公告)号：US20050054062A1
公开(公告)日：2005-03-10
申请号：US10942018
申请日：2004-09-16
申请人： Kazuo Nagai , Masaaki Wachi
发明人： Kazuo Nagai , Masaaki Wachi
IPC分类号： C07K14/34 , C12N1/21 , C12N15/31 , C12P13/14
CPC分类号： C07K14/34 , C12P13/14
摘要： The present invention relates to a protein having an activity of giving a lysozyme insensitivity to a lysozyme-sensitive microorganism belonging to Corynebacterium glutamicum; DNA which codes for the protein; a recombinant vector containing the DNA; a transformant obtained by introducing the recombinant vector into a host cell; a bacterium having a lysozyme sensitivity in which the activity of the protein is inactivated; and a method for producing an amino acid using the bacterium.
摘要翻译：本发明涉及具有对属于谷氨酸棒杆菌的溶菌酶敏感性微生物产生溶菌酶敏感性的活性的蛋白质; 编码蛋白质的DNA; 含有DNA的重组载体; 通过将重组载体导入宿主细胞获得的转化体; 具有其中蛋白质活性失活的溶菌酶敏感性的细菌; 以及使用该细菌生产氨基酸的方法。

6. 发明授权

US07223587B2 Gene conferring lysozyme insensitivity to Corynebacterium 有权
标题翻译：基因赋予溶菌酶对棒状杆菌不敏感
公开(公告)号：US07223587B2
公开(公告)日：2007-05-29
申请号：US10942018
申请日：2004-09-16
申请人： Kazuo Nagai , Masaaki Wachi
发明人： Kazuo Nagai , Masaaki Wachi
IPC分类号： C12N1/20 , C12N15/74
CPC分类号： C07K14/34 , C12P13/14
摘要： The present invention relates to a protein having an activity of giving a lysozyme insensitivity to a lysozyme-sensitive microorganism belonging to Corynebacterium glutamicum; DNA which codes for the protein; a recombinant vector containing the DNA; a transformant obtained by introducing the recombinant vector into a host cell; a bacterium having a lysozyme sensitivity in which the activity of the protein is inactivated; and a method for producing an amino acid using the bacterium.
摘要翻译：本发明涉及具有对属于谷氨酸棒杆菌的溶菌酶敏感性微生物产生溶菌酶敏感性的活性的蛋白质; 编码蛋白质的DNA; 含有DNA的重组载体; 通过将重组载体导入宿主细胞获得的转化体; 具有其中蛋白质活性失活的溶菌酶敏感性的细菌; 以及使用该细菌生产氨基酸的方法。

7. 发明申请

US20060241185A1 Antibiotics targeting MreB 有权
标题翻译：针对MreB的抗生素
公开(公告)号：US20060241185A1
公开(公告)日：2006-10-26
申请号：US11350966
申请日：2006-02-08
申请人： Zemer Gitai , Lucy Shapiro , Masaaki Wachi , Noritaka Iwai
发明人： Zemer Gitai , Lucy Shapiro , Masaaki Wachi , Noritaka Iwai
IPC分类号： A61K31/17 , G06F19/00 , C12Q1/18
CPC分类号： C12Q1/18 , A61K31/17 , Y02A50/473 , Y02A90/22
摘要： The identification of MreB as essential for bacterial chromosome segregation provides a new target for antibiotic action. The MreB function is useful in the development of screening assays for new antibiotics, which may use, for example, genetic mutants in MreB, tests of MreB mediated chromosome segregation, and the like. In one embodiment of the invention, the antibiotic is an isothiourea compound, which may comprise a polyhalogenated benzyl group, e.g. at the 4 position, the 2,4 position, etc. A pharmaceutical composition comprising an MreB targeted antibiotic as an active agent is administered to a patient suffering from a microbial infection, particularly bacterial infections.
摘要翻译：鉴定MreB是细菌染色体分离所必需的，为抗生素作用提供了新的靶标。 MreB功能可用于开发新抗生素的筛选测定，其可以使用例如MreB中的遗传突变体，MreB介导的染色体分离的测试等。在本发明的一个实施方案中，抗生素是异硫脲化合物，其可以包含多卤代苄基，例如，在4位，2,4位等。将包含MreB靶向抗生素作为活性剂的药物组合物施用于患有微生物感染，特别是细菌感染的患者。

8. 发明授权

US06911326B1 GlmU polypeptide and DNA encoding the polypeptide 失效
标题翻译： GlmU多肽和编码多肽的DNA
公开(公告)号：US06911326B1
公开(公告)日：2005-06-28
申请号：US10130419
申请日：2000-11-17
申请人： Kazuo Nagai , Masaaki Wachi
发明人： Kazuo Nagai , Masaaki Wachi
IPC分类号： C12N1/21 , C12N9/12 , C12N15/31 , C12P19/30 , C12P19/26 , C07H21/04 , C12N9/10
CPC分类号： C12N9/1241 , C12P19/305 , C12Y207/07023
摘要： The present invention relates to a polypeptide having the activity of N-acetylglucosamine-1-phosphate uridyltransferase (hereinafter referred to as GlmU), a DNA coding for the polypeptide, a recombinant DNA containing the DNA, a transformant carrying the recombinant DNA, a method of culturing the transformant for producing the GlmU polypeptide, and a method of culturing the transformant for producing uridine 5′-diphosphate-N-acetylglucosamine.According to the present invention, mass-scale production of the GlmU polypeptide derived from microorganisms belonging to the genus Corynebacterium glutamicum has been enabled by genetic recombinant technology. By using the enzyme, uridine 5′-diphosphate-N-acetylglucosamine can be produced efficiently.
摘要翻译：本发明涉及具有N-乙酰葡糖胺-1-磷酸尿苷酰转移酶（以下称为GlmU）的活性的多肽，编码该多肽的DNA，含该DNA的重组DNA，携带重组DNA的转化体，培养用于产生GlmU多肽的转化体，以及培养用于产生尿苷5'-二磷酸-N-乙酰葡糖胺的转化体的方法。根据本发明，通过遗传重组技术已经实现了源自谷氨酸棒状杆菌属的微生物的GlmU多肽的大规模生产。通过使用该酶，可以有效地制备尿苷5'-二磷酸-N-乙酰葡糖胺。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式